dburnsdesign Thank You, John Carr... By DeeDee DeMan - John Carroll, the writer in the Life Science Industry industry we depend on... blog new
dburnsdesign “The Leading &... By DeeDee Deman - What defines a leading edge company in today’s tumultuous Pharma world? It’s a... blog new
dburnsdesign Bench International... By Nikki Webber - Even the smallest contribution to a drug approval is extremely rewarding to the team... blog new
dburnsdesign Novo Nordisk Bucking... By Natasha Allen - Hopefully this pioneering company will pave the way for further investment in the... blog new
dburnsdesign “I Rest My Cas... By DeeDee DeMan - Looking at the 2016 “report card,” on FDA approvals reinforces why we all... blog new
dburnsdesign Decisive, Knowledgea... By DeeDee DeMan - One of the very few things that has made much sense lately is... blog new
dburnsdesign Could the U.S. lose... By Danny Abiri - Noting that the U.S. share of cancer research has been declining over the... blog new
dburnsdesign The Future of Drug D... By Kimberly Plessala. - On the topic of artificial intelligence, I for one, tend towards the Hollywood... blog new
dburnsdesign Brexit – Scien... By Natasha Allen - Nobody likes to feel pressured but there are times where keeping the pressure... blog new
dburnsdesign Advances in Alzheime... By Gail Rosenblum - Advances are being made globally in the area of Alzheimer’s disease and related... blog new
dburnsdesign A top voice in regul... By Tim Silcott - Dr. Scott Gottlieb is a top thought leader when it comes to regulations... blog new
dburnsdesign Another Hindrance to... By Tim Silcott - Gene Therapy has been a top topic in life science for discussion in... blog new
